-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2023-503517-30-00
5
2022-04-01
Extensive-stage small-cell lung cancer
-
2023-509631-37-00
5
2022-01-18
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
-
2023-508308-40-00
5
2021-07-30
Metastatic (stage IV) squamous or nonsquamous non-small cell lung canc
-
2023-504997-39-00
5
2021-06-14
Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
-
2023-503995-26-00
5
2021-05-11
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
-
2023-509405-77-00
5
2021-02-16
Colorectal cancer (BRAF V600E-mutant mCRC)
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2022-502982-49-00
4
2024-07-15
Metastatic Castration-Resistant Prostate Cancer
-
2022-501078-20-00
4
2023-05-15
Metastatic Castration-resistant Prostate Cancer
-
2023-505458-16-00
5
2022-09-13
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
-
2023-506074-12-00
5
2022-03-22
Metastatic Non-Small Cell Lung Cancer
-
2023-504834-23-00
11
2021-02-24
Advanced/Metastatic Gastroesophageal Adenocarcinoma
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2023-508449-41-00
5
2019-06-26
Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
-
2023-509774-40-00
5
2019-06-25
Stage IV lung cancer condition
-
2023-508890-10-00
5
2018-12-05
Gastric and gastric esophageal junction (GEJ) adenocarcinoma
-
2023-508253-98-00
5
2018-10-05
Gastric or gastroesophageal junction (GEJ) adenocarcinoma
-
2022-501251-81-00
5
2017-06-08
Renal cell carcinoma
-
2023-506487-13-00
5
Hormone receptor-positive, her2-negative advanced/metastatic breast ca